Navigation Links
CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of CoLucid Pharmaceuticals, Inc.; Is $46.50 a Fair Price?
Date:1/18/2017

SAN DIEGO, Jan. 18, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Company. CoLucid is a biopharmaceutical company that develops small molecules for the acute treatment of migraines.

On January 18, 2017, CoLucid announced it had signed a definitive merger agreement with Eli Lilly. Under the terms of the agreement, Eli Lilly will acquire all shares of CoLucid Pharmaceuticals for a purchase price of $46.50 per share.

The investigation concerns whether the CoLucid board failed to satisfy their duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for CoLucid shares of common stock. Nationally recognized Johnson & Weaver is investigating whether the proposed deal price represents adequate consideration, especially given one Wall Street analyst has a $58 price target on the stock. 

If you are a shareholder of CoLucid and believe the proposed buyout price is too low and you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471.

About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/colucid-clcd-alert-johnson--weaver-llp-launches-an-investigation-into-the-fairness-of-price-and-process-in-proposed-sale-of-colucid-pharmaceuticals-inc-is-4650-a-fair-price-300392666.html


'/>"/>
SOURCE Johnson & Weaver, LLP
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
2. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
4. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
5. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
6. Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness"
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL
8. INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
9. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc.
10. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc.
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avalanche Biotechnologies, Inc. - AAVL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... ... 2020 , ... Anomet Products has introduced new ... in harsh environments inside or outside of the human body. , ... to achieve specific properties such as corrosion-resistance, biocompatibility, or operation at temperatures from ...
(Date:1/7/2020)... ... January 07, 2020 , ... Vuja De Sciences (“Vuja ... and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM (Onc), and ... of Vuja De said, “We are delighted to welcome Chand and Lee as new ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... of emerging biosciences ventures invited to participate in the annual program. Twelve ventures ... business plans and a professional network. All startups will receive an entrepreneur coach, ...
(Date:12/30/2019)... TOWNSHIP, N.J. (PRWEB) , ... December 30, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... SIMS Version 1.11.19 21 CFR Part 11 compliant software program specific to the ...
Breaking Biology Technology:
(Date:12/18/2019)... ... December 18, 2019 , ... Intelligent.com, a ... Top 10 Master's in Biotechnology Degree Programs for 2020. The comprehensive research guide ... nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and ...
(Date:12/4/2019)... , ... December 03, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... a partnership with Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using ...
(Date:11/27/2019)... ... 26, 2019 , ... Smile Glen Ellyn dentists, Drs. Thomas ... Invisalign® treatment. Invisalign orthodontics uses a series of clear, virtually invisible aligners ... as malocclusion, present both functional and cosmetic concerns. Functionally, crooked teeth ...
Breaking Biology News(10 mins):